Clinical trials: Allogeneic Disease
Leukemia, Myelodysplastic Syndrome
Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen
1. At the same time of registration, patients will be randomized to one of the two conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or Arm II (intravenous busulfan plus fludarabine; BuFlu). 2.
- Trial name
- BuCyvsBUFlu (NCT00774280)
- Testing
- BuCy vs BuFlu
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Cooperative Study Group A for Hematology
Hematologic Malignancy
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.
- Trial name
- NCT03986086
- Testing
- MPH966
- Where
- United States
- Sponsor
- Nelson Chao
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Thrombotic Disorder
The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation
We aim to assess the the efficiency and safety of N-acetylcysteine for prevention of thrombotic events after allogenic hematopoietic stem cell transplantation.
- Trial name
- NCT05907486
- Testing
- N-acetyl-cysteine, Busulfan, Cytarabine
- Volunteers
- 260 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Acute Ischemic Stroke, Mesenchymal Stem Cells
Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)
The purpose of this study is to use an intravenous infusion of allogeneic human mesenchymal stem cells (Allo-hMSCs) to treat an acute ischemic stroke condition.
- Conditions
- Acute Ischemic Stroke, Mesenchymal Stem Cells, Stroke, Acute, Stroke/Brain Attack
- Trial name
- EXPAND (NCT05522569)
- Testing
- Allogeneic human mesenchymal stem cells (Allo-hMSCs)
- Where
- United States
- Sponsor
- University of Miami
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Small Cell Lung Cancer
NK Cells Plus ICI for SCLC Maintenance
This research study is designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard chemotherapy, with at least two cycles combined with immunotherapy, and have…
- Trial name
- NK-ICI-SCLC (NCT07759856)
- Testing
- Allogeneic Natural Killer Cells, Immune Checkpoint Inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Tianjin First Central Hospital
Myelodysplastic Syndrome, Acute Myeloblastic Leukemia
Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients
Primary Objective: 1. To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloblastic Leukemia, Leukemia
- Trial name
- NCT00504920
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Critical Limb Ischemia Due to Buerger's Disease
A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease
This study is being conducted as an extension of the phase II clinical trial SRPL/CLI/10-11/001 (NCT01484574). The CDSCO has recommended flexibility for continued clinical study in consultation with ICMR, as per recommendation of…
- Trial name
- NCT03056742
- Testing
- Stempeucel(R)
- Where
- 8 sites in India
- Sponsor
- Stempeutics Research Pvt Ltd
Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
This phase I trial tests the safety, side effects, best dose and effectiveness of revumenib in treating patients with acute leukemia after allogeneic stem cell transplant.
- Conditions
- Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT06575296
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, in Relapse
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the…
- Trial name
- GITMO-RELAPSE (NCT05124288)
- Testing
- Observations on Relapsed AML Allogeneic Transplanted patients
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Ciceri Fabio
MPS-IH (Hurler Syndrome)
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
A multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
- Trial name
- HURCULES (NCT06149403)
- Testing
- Experimental: OTL-203, Active Comparator: Allo-HSCT
- Where
- 5 sites in United States, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Orchard Therapeutics
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Ruxolitinib as GVHD Prophylaxis in AA Patients
Our study aimed to determine the prophylactic value of ruxolitinib for aGVHD in HSCT recipients of AA.Ruxolitinib was initiated at the beginning of conditioning regimen at 5 twice daily until 3 months post-transplantation.
- Trial name
- NCT05914714
- Testing
- Ruxolitinib 5 MG BID Oral Tablet
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Cornea Disease
A Single-Center Clinical Study Evaluating the Efficacy and Safety of Allogeneic Natural Killer (NK) Cell Transplantation for Mooren's Ulcer
Given that the definitive pathogenesis of Mooren's ulcer has not been fully clarified and clinical relapse occurs frequently, natural killer (NK)-cells demonstrate unique therapeutic potential.
- Trial name
- NCT07782138
- Testing
- Allogeneic natural killer (NK)-cell transplantation
- Volunteers
- 6 people
- Sponsor
- Suxia Li
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease…
- Trial name
- NCT05020015
- Testing
- TAK-007, Chemotherapy Agents
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- Takeda
Progressive Multifocal Leucoencephalopathy (PML)
T-cell Therapy in Patients With PML
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment.
- Trial name
- NCT06990087
- Testing
- Application of T-lymphocytes
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Hannover Medical School
Bronchiolitis Obliterans Syndrome (BOS), HSCT
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease
- Trial name
- IMMUNO-BOS (NCT07771855)
- Testing
- Tezepelumab
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- Hopital Foch
Hemophagocytic Lymphohistiocytosis
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the…
- Trial name
- HELA2012 (NCT01547143)
- Testing
- IST and/or alloHCT
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Asan Medical Center
Relapsed or Refractory Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Acute myeloid leukemia (AML) is one of the hematologic malignancies, for which patients typically undergo chemotherapy to achieve complete remission.
- Trial name
- NCT06879847
- Testing
- Salvage Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.